In 2009, total funding for European and U.S. biotechs dwarfed the dismal levels seen in 2008. The European sector raised $6.3 billion last year, up 202% from $2.1 billion in 2008, driven by three companies. Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) pulled in $640.4 million from a follow-on in 2009, and Elan Corp. plc